drugset / Trial / NCT00171522

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

NCT00171522

Phase 4 Completed 52 enrolled Novartis
RandomizedCrossoverOpen-labelTreatment

Summary

To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste

Timeline

Start
2005-05
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tegaserod Small molecule
Subject polyethylene glycol Other / unclassified 3350 unknown

Indications